Wegovy vs Foundayo: Injection vs the New GLP-1 Pill

    Wegovy vs Foundayo: Injection vs the New GLP-1 Pill

    Wegovy injection led Foundayo on weight loss in separate trials (14.9% vs 11.1%); no head-to-head trial exists. Dosing, side effects, uses and dated prices.

    Written by Diana Gangan. Updated November 16, 2026.

    Wegovy, the weekly semaglutide injection, produced more weight loss in its main trial than Foundayo, the daily orforglipron pill, did in its trial, but the two have never been tested against each other, so that gap is an estimate, not a proven difference. In STEP 1, people on Wegovy 2.4 mg lost 14.9% of their body weight at 68 weeks, against 2.4% on placebo. In the main Foundayo trial, the highest dose (17.2 mg) produced an 11.1% loss at 72 weeks, against 2.1% on placebo. Foundayo, approved by the FDA on April 1, 2026, is a once-daily tablet that can be taken with or without food. Wegovy is a once-weekly pen and has uses Foundayo lacks, including heart risk reduction, a liver disease called MASH, and treatment for teenagers. Side effects are similar in type, mostly nausea, diarrhea, vomiting and constipation. This guide compares the two on results, dosing, side effects and reported prices, and explains where the Wegovy pill fits.

    Wegovy vs Foundayo: The Short Answer

    1. 1Form: Wegovy is a once-weekly injection (a Wegovy pill also exists); Foundayo is a once-daily tablet with no food or water rules.
    2. 2Weight loss: about 14.9% with Wegovy 2.4 mg in STEP 1 vs 11.1% with Foundayo 17.2 mg in its main trial; no head-to-head trial exists.
    3. 3Side effects: both mainly cause digestive effects; nausea was reported in 44% on Wegovy 2.4 mg and 35% on Foundayo 17.2 mg in their label trials.
    4. 4Other uses: Wegovy is also approved for heart risk reduction, MASH and ages 12 and up; Foundayo is approved for adult weight management only.
    5. 5Price: reported self-pay prices at launch were $349 a month for the Wegovy injection and $149 to about $349 for Foundayo, depending on dose and source.

    What Is Foundayo, and When Was It Approved?

    Foundayo (orforglipron) is made by Eli Lilly and was approved by the FDA on April 1, 2026. It is an oral small-molecule GLP-1 receptor agonist, meaning a pill that acts on the same hormone receptor as semaglutide but is not a peptide (protein-based) drug. According to its label (revised July 2026), it is approved for chronic weight management, together with a reduced-calorie diet and more physical activity, in adults with obesity, or with overweight plus at least one weight-related condition. It is not approved for type 2 diabetes, and it should not be combined with another GLP-1 drug. Like Wegovy, it carries a boxed warning about thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN 2).

    How Do Wegovy and Foundayo Work?

    Both drugs activate the same target, the GLP-1 receptor. Wegovy contains semaglutide, a peptide that is given as an injection under the skin once a week (or, in the newer Wegovy pill, taken daily with strict fasting rules). Foundayo is a small molecule, a different type of chemical, and Lilly describes it as a pill that can be taken "any time of the day without restrictions on food and water intake." That is the company's wording; the label itself says it can be taken with or without food.

    Which Causes More Weight Loss, Wegovy or Foundayo?

    The two drugs have not been compared in the same trial, so any comparison is across trials with different people, lengths and methods. With that caveat, the label and trial numbers are below.

    1. 1Wegovy injection 2.4 mg (STEP 1, 1,961 adults): 14.9% weight loss at 68 weeks vs 2.4% on placebo.
    2. 2Wegovy injection 7.2 mg: about 14.9% greater weight loss than placebo at 72 weeks (label Study 8, 1,407 people). This higher dose is covered in our Wegovy 7.2 mg guide.
    3. 3Foundayo 17.2 mg (label Trial 1, adults without diabetes): 11.1% at 72 weeks vs 2.1% on placebo, or 9.0 points more than placebo.
    4. 4Foundayo 17.2 mg (label Trial 2, adults with type 2 diabetes): 9.6% vs 2.5% on placebo.

    Lilly's approval release reported that in ATTAIN-1 (3,127 participants, 72 weeks), the highest dose produced 12.4% loss when counting only people who kept taking the drug as intended, and 11.1% when counting everyone assigned to it, against 0.9% and 2.1% on placebo. A trade-press report adds that ATTAIN used an earlier 36 mg capsule formulation; we could not confirm how that relates to the 17.2 mg tablet on the label. Typical Wegovy results are covered in how much weight you can lose on Wegovy.

    Foundayo dose vs weight loss at 72 weeks (label trials)

    Foundayo dose
    Trial 1 (no diabetes)
    Trial 2 (type 2 diabetes)

    Placebo

    -2.1%

    -2.5%

    5.5 mg daily

    -7.4%

    Not in sources used

    9 mg daily

    -8.3%

    Not in sources used

    17.2 mg daily

    -11.1% (-9.0% vs placebo)

    -9.6%

    How Do You Take Wegovy and Foundayo?

    Wegovy is injected under the skin once a week on the same day, using a prefilled pen. If you miss a dose and your next one is more than 2 days away, the label says to take it as soon as possible; otherwise skip it. Unopened pens are kept in the refrigerator, although they can be kept at 46°F to 86°F (8°C to 30°C) for up to 28 days before the cap is removed; see our Wegovy storage guide.

    Foundayo is one tablet a day, swallowed whole, with or without food. A missed dose should be taken as soon as possible, without doubling up. If 7 or more doses in a row are missed, the label says treatment should restart at a lower dose. Foundayo is stored at room temperature, 68°F to 77°F (20°C to 25°C), with short excursions from 59°F to 86°F allowed. One practical point: Foundayo can make birth control pills less reliable, so the label advises switching to a non-oral method, or adding a barrier method such as condoms, for 30 days after starting and for 30 days after each dose increase.

    How Do the Wegovy and Foundayo Dose Schedules Compare?

    Both drugs start low and increase gradually to limit side effects. These schedules come from the labels and are set by your prescriber.

    1. 1Wegovy injection: 0.25 mg, 0.5 mg, 1 mg and 1.7 mg weekly, four weeks each, then 2.4 mg maintenance from week 17 (1.7 mg is an alternative). For weight reduction, the dose can go up to 7.2 mg if 2.4 mg has been tolerated for at least four weeks.
    2. 2Foundayo: 0.8 mg, then 2.5 mg, then 5.5 mg daily, at least 30 days at each step, then 9 mg, 14.5 mg or 17.2 mg depending on response and tolerability. The maximum is 17.2 mg daily, or 9 mg in people taking strong CYP3A4 inhibitors (certain medicines that slow how the drug is broken down).

    Our Wegovy dosing schedule explains the injection steps and missed doses in more detail.

    Which Has More Side Effects, Wegovy or Foundayo?

    Both cause mostly digestive side effects, especially while the dose is being increased. In their label trials, nausea was reported by 44% on Wegovy 2.4 mg (vs 16% on placebo) and by 35% on Foundayo 17.2 mg (vs 10% on placebo). Diarrhea was 30% vs 16% for Wegovy and 25% vs 11% for Foundayo 17.2 mg; vomiting 24% vs 6% and 24% vs 4%; constipation 24% vs 11% and 24% vs 9%. Side effects stopped treatment for 6.8% on Wegovy 2.4 mg (vs 3.2% on placebo) and for 10% on Foundayo 17.2 mg (8% across all Foundayo doses, vs 3% on placebo). These come from separate trials, so small differences may not be meaningful.

    Wegovy injection, Wegovy pill and Foundayo compared (label and trial data; prices as reported at launch)

    Feature
    Wegovy injection
    Wegovy pill
    Foundayo

    FDA approval

    Earliest of the three; 7.2 mg dose on current label

    December 22, 2025

    April 1, 2026

    How taken

    Injection, once weekly

    Tablet, once daily

    Tablet, once daily

    Label maintenance dose

    2.4 mg (up to 7.2 mg for weight)

    25 mg

    9 mg, 14.5 mg or 17.2 mg

    Food and water rules

    None tied to meals

    Empty stomach in the morning, up to 4 oz water, wait 30 minutes

    With or without food

    Key trial weight loss

    -14.9% vs -2.4% (STEP 1, 68 weeks)

    About 11.2% more than placebo (64 weeks)

    -11.1% vs -2.1% (72 weeks, 17.2 mg)

    Nausea (drug vs placebo)

    44% vs 16% (2.4 mg)

    Not in sources used

    35% vs 10% (17.2 mg)

    Stopped for side effects

    6.8% vs 3.2%

    6.9% vs 5.9%

    10% (17.2 mg) vs 3%

    Storage

    Refrigerate; up to 28 days at 46°F to 86°F before cap removed

    See label

    68°F to 77°F

    Reported self-pay price

    $349/month (Reuters, Apr 1, 2026)

    $149 to $299/month by dose (Reuters, Apr 1, 2026)

    From $149/month; $299 to about $349 at higher doses (Lilly, Reuters, Apr 2026; trade press, May 2026)

    What Other Uses Does Wegovy Have That Foundayo Doesn't?

    The Wegovy injection label covers more than weight loss in adults. It is also approved for weight management in children 12 and older (see Wegovy for teens), for reducing the risk of major heart events such as heart attack and stroke in certain adults (see the SELECT trial), and for noncirrhotic MASH, a serious form of fatty liver disease (see Wegovy for MASH). Foundayo is approved only for adult weight management as of November 2026. Lilly reported diabetes trials in June 2026, including ACHIEVE-3, in which Foundayo lowered A1C (average blood sugar) by 1.9% at 9 mg and 2.2% at 17.2 mg, against 1.1% and 1.4% for oral semaglutide at 7 mg and 14 mg. That trial compared Foundayo with the diabetes pill form of semaglutide, not with Wegovy. Lilly planned to file for a diabetes approval in the second quarter of 2026; we have not confirmed an approval.

    How Much Do Wegovy and Foundayo Cost?

    Prices change often, and reported figures conflict, so treat these as launch-period numbers, not current quotes. All are self-pay prices without insurance.

    1. 1Foundayo (Lilly, April 1, 2026): self-pay through LillyDirect from $149 a month for the lowest dose, and as little as $25 a month with Lilly's savings card for people with commercial insurance. Lilly said Medicare Part D patients might pay $50 a month from July 1, 2026.
    2. 2Foundayo by dose (Managed Healthcare Executive, May 2026): $149 for 0.8 mg, $199 for 2.5 mg, and $299 for 5.5 mg and higher.
    3. 3Foundayo (Reuters, April 1, 2026): about $349 a month for most patients, or $299 with refill incentives. This conflicts with the trade-press figures above, and we could not confirm which applies today.
    4. 4Wegovy injection (Reuters, April 1, 2026): $349 a month self-pay for doses from 0.25 mg to 2.4 mg. We have not verified later price changes.
    5. 5Wegovy pill (Reuters, April 1, 2026): $149 for 1.5 mg; $149 for 4 mg through August 31, 2026, then $199; $299 for 9 mg and 25 mg.

    Insurance coverage varies by plan; see does insurance cover Wegovy.

    Where Does the Wegovy Pill Fit?

    Most online comparisons pit Foundayo against the Wegovy pill rather than the injection. The Wegovy pill (oral semaglutide 25 mg) was approved on December 22, 2025. It starts at 1.5 mg and increases to 4 mg and 9 mg, 30 days each, then 25 mg daily. Unlike Foundayo, it must be taken on an empty stomach in the morning with up to 4 ounces of water, followed by a wait of at least 30 minutes before eating, drinking or taking other oral medicines. In the label trial it produced about 11.2% more weight loss than placebo at 64 weeks; Novo Nordisk reported a 16.6% mean loss in OASIS 4 among people who took it as directed, and trade press reported a 13.6% mean loss. Our Wegovy pill vs injection comparison and how to take the Wegovy pill cover it in more depth.

    Can You Switch From Wegovy to Foundayo?

    Neither label gives instructions for switching between them, so there is no official conversion. If you are thinking about switching, for example to avoid injections, your prescriber will decide the starting dose and timing.

    When to Talk to Your Doctor

    1. 1Before starting either drug if you or a family member has had medullary thyroid cancer or MEN 2
    2. 2If you rely on birth control pills and are considering Foundayo
    3. 3If you have heart disease or fatty liver disease, where Wegovy has approved uses Foundayo lacks
    4. 4If you have severe stomach pain, persistent vomiting or signs of dehydration on either drug
    5. 5If you want to switch between Wegovy and Foundayo, or between the pill and the pen

    Which Might Suit You? Questions to Ask Your Doctor

    1. 1Is a weekly injection or a daily pill a better fit for my routine?
    2. 2Do my heart, liver or diabetes conditions make one drug a better choice?
    3. 3Which medicines I take could interact, such as birth control pills or CYP3A4 inhibitors?
    4. 4What will I actually pay with my insurance or a savings program?
    5. 5How will we judge whether the drug is working, and when?

    The Bottom Line

    Wegovy and Foundayo both work through the GLP-1 receptor and both cause meaningful weight loss. On the trial numbers, the Wegovy injection produced more weight loss (14.9% at 2.4 mg) than Foundayo at its highest dose (11.1%), and Wegovy has extra approved uses. Foundayo's main advantage is convenience: a daily pill with no food or water rules. No trial has compared them directly, side effects are similar in type, and reported prices conflict, so the choice depends on your health conditions, preferences and coverage.

    FAQ

    In separate trials, Foundayo 17.2 mg produced 11.1% weight loss at 72 weeks, and Wegovy 2.4 mg produced 14.9% at 68 weeks. No head-to-head trial exists, so the gap is an estimate.

    The labels give no switching instructions. Your prescriber would decide the starting dose and timing.

    No. The label says Foundayo can be taken with or without food. The Wegovy pill, by contrast, must be taken on an empty stomach with up to 4 ounces of water.

    Both mainly cause nausea, diarrhea, vomiting and constipation. Nausea affected 35% on Foundayo 17.2 mg and 44% on Wegovy 2.4 mg in separate label trials; stopping due to side effects was 10% and 6.8%.

    At launch in April 2026, Lilly listed self-pay prices from $149 a month for the lowest dose. Reports for higher doses conflict, ranging from $299 (trade press, May 2026) to about $349 a month (Reuters, April 2026).

    Not according to its July 2026 label, which covers weight management only. Lilly planned a diabetes filing in the second quarter of 2026; we have not confirmed an approval.

    Sources

    This article is general information based on FDA labels and published trials, and it is not medical advice. Several sources are company materials from the manufacturers, Novo Nordisk and Eli Lilly; prices are as reported on the dates shown and may have changed.

    Diana Gangan

    Author

    Published November 16, 2026
    Share:TwitterFacebook

    Comments (0)

    Be the first to comment on this article.

    More articles

    GLP-1 Drugs Explained: Types, Benefits, Risks, and How They Help With Weight Loss